Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
29 Maggio 2024 - 2:00PM
Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us”
or the “Company”), a clinical-stage biotechnology company
addressing serious diseases with significant unmet need, today
announces an abstract publication at the 2024 American Society of
Clinical Oncology (ASCO) annual meeting, taking place from May 31 -
June 4 in Chicago, IL, and online.
Lipella’s abstract, titled “Intravesical Administration of
Pembrolizumab for Bladder Tumor- A Potential Strategy to Minimize
Drug Toxicity” highlights new preclinical results from LP-50
(intravesical pembrolizumab) in induced murine non-muscle invasive
bladder cancer (NMIBC). The abstract can be viewed at:
https://meetings.asco.org/abstracts-presentations/235302.
Lipella Pharmaceuticals Chief Medical Officer, Dr. Michael
Chancellor, said, “LP-50 is an intravesical formulation intended
for the treatment of non-muscle invasive bladder cancer. Our
preclinical results have demonstrated promising results,
demonstrating LP-50’s potential for increasing efficacy while
minimizing systemic toxicity.”
The American Cancer Society estimates that there will be 83,190
new cases of bladder cancer diagnosed in the United States in
2024.
About LP-50 LP-50 is an intravesical
formulation of immunoglobulins including local, intravesical PD-1
(i.e. checkpoint) inhibition, intended for the treatment of
non-muscle invasive bladder cancer (NMIBC), offering the potential
for increasing efficacy while minimizing systemic toxicity.
Additional information regarding this preclinical program is
included in the International Journal of Molecular Sciences 2024,
25(9), 4945, titled "Enhancing Therapeutic Efficacy and Safety of
Immune Checkpoint Inhibition for Bladder Cancer: A Comparative
Analysis of Injectable vs. Intravesical Administration," as well as
in US patent publication number 2024/0115503 titled "Intravesical
Delivery of Hydrophilic Therapeutic Agents Using Liposomes."
About Lipella Pharmaceuticals Inc.Lipella
Pharmaceuticals is a clinical-stage biotechnology company focused
on developing new drugs by reformulating the active agents in
existing generic drugs and optimizing these reformulations for new
applications. Additionally, Lipella maintains a therapeutic focus
on diseases with significant, unaddressed morbidity and mortality
where no approved drug therapy currently exists. Lipella completed
its initial public offering in December 2022.
Forward-Looking StatementsThis press release
includes certain "forward-looking statements." All statements,
other than statements of historical fact, included in this press
release regarding, among other things, our strategy, future
operations, financial position, prospects, clinical trials,
regulatory approvals, pipeline and opportunities, sources of
growth, successful implementation of our proprietary technology,
plans and objectives are forward-looking statements.
Forward-looking statements can be identified by words such as
"may," "will," "could," "continue," "would," "should," "potential,"
"target," "goal," "anticipates," "intends," "plans," "seeks,"
"believes," "estimates," "predicts," "expects," "projects" and
similar references to future periods. Forward-looking statements
are based on our current expectations and assumptions regarding
future events and financial trends that we believe may affect among
other things, market and other conditions, our financial condition,
results of operations, business strategy, short- and long-term
business operations and objectives, and financial needs. Because
forward-looking statements relate to the future, they are subject
to inherent uncertainties, risks and changes in circumstances that
are difficult to predict. Our actual results may differ materially
from those contemplated by the forward-looking statements. We
caution you, therefore, against relying on any of these
forward-looking statements. They are neither statements of
historical fact nor guarantees or assurances of future performance.
There are risks, uncertainties and other factors, both known and
unknown, that could cause actual results to differ materially from
those in the forward-looking statements which include, but are not
limited to, risks related to the effective application of the use
of proceeds from the private placement, general capital market
risks, regional, national or global political, economic, business,
competitive, market and regulatory conditions, and other factors.
Any forward-looking statement made by us is based upon the
reasonable judgment of our management at the time such statement is
made and speaks only as of the date on which it is made. Factors or
events that could cause our actual results to differ may emerge
from time to time, and it is not possible for us to predict all of
them. We undertake no obligation to update any forward-looking
statement, whether as a result of new information, future
developments or otherwise, except as may be required by applicable
law. Nothing contained herein is, or shall be relied upon as, a
promise or representation as to the past or future. In addition,
the information contained in this press release is as of the date
hereof, and the Company has no obligation to update such
information, including in the event that such information becomes
inaccurate. You should not construe the contents of this press
release as legal, tax and financial advisors as to legal and
related matters concerning the matters described herein.
CONTACTJonathan KaufmanChief Executive
OfficerLipella Pharmaceuticals Inc. Info@Lipella.com
1-412-894-1853
PCG AdvisoryJeff
Ramsonjramson@pcgadvisory.com
Grafico Azioni Lipella Pharmaceuticals (NASDAQ:LIPO)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Lipella Pharmaceuticals (NASDAQ:LIPO)
Storico
Da Dic 2023 a Dic 2024